A Study of Daratumumab
Running, not enrolling · Phase 3
Conditions studied: Multiple Myeloma
In brief
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have reached clinical cutoff for final analysis. Certain long-term safety data will continue to be collected from study participants.
Key facts
- Study ID
- NCT05438043
- Run by
- Janssen Research & Development, LLC
- People needed
- 213
- Starts
- 2022-12-15
- Expected to finish
- 2029-12-31
- Last updated by the study team
- 2026-07-31
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participants must be actively receiving daratumumab (either as monotherapy or in combination with other study treatment) in certain Janssen research and development (R\&D) studies or receiving other study treatment in a Janssen R\&D daratumumab study for participants with multiple myeloma or smoldering multiple myeloma which has reached clinical cutoff for final analysis continue to benefit from study treatment, not have experienced disease progression or unmanageable toxicity while receiving daratumumab, not have met the withdrawal criteria set forth in the parent study, and have had the last dose of study treatment within the previous 3 months
- Investigator's assessment that the benefit of continued study treatment will outweigh the risks
- A female participant of childbearing potential must have a negative pregnancy test at screening and must agree to further serum or urine pregnancy tests during the study
- A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 3 months after receiving the last dose of study treatment
- Must sign an informed consent form (ICF; or their legally acceptable representative must sign) indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study
- Willing and able to adhere to the lifestyle restrictions specified in this protocol
You may not qualify if…
- Has taken any disallowed therapies or treatment for the disease under study between the completion of the parent study and the planned first dose of study treatment
- Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
- Known allergies, hypersensitivity, or intolerance to study treatments or their excipients (refer to the daratumumab investigator brochure (IB) and local country prescribing information for dexamethasone, carfilzomib, pomalidomide, and lenalidomide)
- Vaccinated with an investigational vaccine (except for Coronavirus disease [COVID-19])or live attenuated or replicating viral vector vaccines within 4 weeks prior to enrollment
Where it is running
- University of Miami Sylvester Cancer Center — Miami, Florida, United States
- Emory University — Atlanta, Georgia, United States
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
- Barnes-jewish Hospital — St Louis, Missouri, United States
- Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg — New York, New York, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Baylor University Medical Center — Dallas, Texas, United States
- ZAS Cadix — Antwerp, Belgium
- UNICAMP — Campinas, Brazil
- Liga Norte Riograndense Contra O Cancer — Natal, Brazil
- Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS — Porto Alegre, Brazil
- Ministerio da Saude Instituto Nacional do Cancer — Rio de Janeiro, Brazil
- COI Clinicas Oncologicas Integradas — Rio de Janeiro, Brazil
- Real e Benemerita Associacao Portuguesa de Beneficencia — São Paulo, Brazil
- Clinica Medica Sao Germano S/S LTDA — São Paulo, Brazil
- Peking Union Medical College Hospital — Beijing, China
- Beijing Chaoyang Hospital — Beijing, China
- Peking University First Hospital — Beijing, China
- Peking University People's Hospital — Beijing, China
- The First Bethune Hospital of Jilin University — Changchun, China
- West China Hospital Si Chuan University — Chengdu, China
- Fujian Medical University — Fuzhou, China
- Guangdong General Hospital — Guangzhou, China
- Nanfang Hospital — Guangzhou, China
- Aarhus University Hospital — Aarhus N, Denmark
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.